Bicara Therapeutics CEO Claire Mazumdar sold 1,596 shares of the company's stock for $30,244.20 on March 20, 2026, continuing a series of insider sales in March. Despite these sales, Mazumdar still holds over 339,000 shares valued at approximately $6.43 million. The company's stock recently traded around $18.41, with a market cap of $1.01 billion and a moderate analyst consensus rating of "Moderate Buy." Bicara focuses on developing neurohormone-based therapies for psychiatric and neurological disorders, with promising drug candidates in clinical stages. Investors may watch for further insider activity and clinical progress as key indicators for the stock's future performance.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Ethereum (ETH) has outperformed Bitcoin (BTC) in Q3, driven by a rally sparked by a softer CPI report and strong on-chain metrics. The recent surge pushed ETH above $1,900, triggering significant liquidations in futures positions. However, ETH now fa...
Solana's number of wallets holding tokenized real-world assets (RWAs) has exceeded 300,000, surpassing Ethereum's roughly 200,000 holders. While Solana's RWA value doubled in 2026 to $3.45 billion, Ethereum still leads with $16.3 billion in tokenized...
Baidu's board has approved a plan to convert to a dual-primary listing on the Hong Kong Stock Exchange's Main Board, alongside its existing Nasdaq listing. This move aims to enhance the liquidity of Baidu's shares, broaden its investor base, and prov...
